A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00131300

Enrollment

Unknown

Registered

2005-08-18

Start date

2004-04-30

Completion date

2006-02-28

Last updated

2015-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases, Osteoarthritis

Keywords

Osteoarthritis of the shoulder, Musculoskeletal

Brief summary

This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic shoulder osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the 3 month follow up period.

Interventions

DEVICESynvisc (hylan G-F 20)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with symptomatic OA pain of shoulder (gleno-humeral)

Exclusion criteria

* Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety

Design outcomes

Primary

Measure	Time frame
Pain relief	—

Countries

France, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026